Latest & greatest articles for tuberculosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on tuberculosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on tuberculosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for tuberculosis

1. Evaluation of Breast Cancer (BC) Awareness among Female University Students in Zarqa University, Jordan (PubMed)

Evaluation of Breast Cancer (BC) Awareness among Female University Students in Zarqa University, Jordan 30288493 2018 11 14 14 4 2018 Oct European journal of breast health Eur J Breast Health Evaluation of Breast Cancer (BC) Awareness among Female University Students in Zarqa University, Jordan. 199-204 10.5152/ejbh.2018.4048 The purposes of this study were to assess the level of Breast Cancer (BC) awareness of Jordanian female university students, measure their attitudes toward BC treatment (...) students who had poor levels of awareness of BC, general knowledge about BC scale, knowledge about BC symptoms scale, and knowledge about risk factors of BC scale were was 270 (83%), 166 (51%), 182 (56%) and 292 (90%), respectively. Also, 92 (28%) students and 234 (72%) students had high and medium attitudes toward BC treatment, respectively. There were significant differences between the humanities and science faculties students' awareness about BC and their attitudes toward BC treatment (p<0.05

Full Text available with Trip Pro

2018 European journal of breast health

2. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy

De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy 28682681 2017 07 06 2017 09 15 2017 09 15 1527-7755 35 26 2017 Sep 10 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. De-Escalation Strategies in Human Epidermal Growth Factor (...) Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET. 3046-3054 10.1200/JCO.2016.71.9815 Purpose Human

2017 EvidenceUpdates

4. BC Neonatal Transfer Record (Form #1600)

BC Neonatal Transfer Record (Form #1600) PSBC 1600 – JANUARY 2017 © Perinatal Services BC PAGE 1 of 2 British Columbia Neonatal Transfer Record 1. Surname Given Name Date / Time of Birth Gestational Age at Birth weeks / days Post Menstrual Age weeks / days Birth Weight / grams Sex ? M ? F ? Unk. Neonatal Daily Classification Sending Facility Attending MD / RM Discharge Diagnosis Today’s Weight / grams Receiving Facility Receiving Physician Maternal / Birth History G T P A L APGAR Scores Surname (...) ., blood from lab tests) 7. Medications: Name / Dose / Route / Frequency ? Medication record attached 1. Last Given Next Due 4. Last Given Next Due 2. 5. 3. 6. 8. Treatments + / or Investigations ? Abnormal Lab Values + / or Blood Culture Results attachedPSBC 1600 – JANUARY 2017 © Perinatal Services BC PAGE 2 of 2 9. Screening ? CCHD Screen Done Date: ? Passed Follow-up: ? Eye Exam Done Date of Last Exam: Due: Results: ? Hearing Screen Done Date: ? Passed Follow-up: ? Newborn Screen Done (blood spot

2014 British Columbia Perinatal Health Program

5. Prescription drug costs: BC versus Canada

Prescription drug costs: BC versus Canada [72] Prescription drug costs: BC versus Canada | Therapeutics Initiative Independent Healthcare Evidence > > [72] Prescription drug costs: BC versus Canada In December 2008, the University of BC Centre for Health Services and Policy Research (CHSPR) published its second edition of the Canadian Rx Atlas on its website. In this Letter we highlight the findings that compare the cost of prescription drugs in BC to Canada as a whole. We also summarize (...) the therapeutic categories where BC physicians prescribe less than, equal to and more than the Canadian average. How were the data in the Canadian Rx Atlas produced? The Atlas reports information on retail sales of all prescription medicines sold in Canada, regardless of formulation (e.g. tablets, liquids, creams, inhaled medicines). It excludes non-prescription and hospital drugs. IMS Health Canada (a pharmaceutical market research firm) provided the patient specific data, which it collects anonymously from

2008 Therapeutics Letter

6. Use of Benzodiazepines in BC ? Is it consistent with recommendations?

Use of Benzodiazepines in BC ? Is it consistent with recommendations? [54] Use of Benzodiazepines in BC – Is it consistent with recommendations? | Therapeutics Initiative Independent Healthcare Evidence > > [54] Use of Benzodiazepines in BC – Is it consistent with recommendations? Therapeutics Letter #11, on the treatment of insomnia, concluded: “If indicated, prescribe benzodiazepines with short half-lives, in low doses, for short duration, and not for regular nightly use.” Therapeutics Letter (...) #18, on the management of anxiety disorders, concluded: “Current evidence suggests that non-benzodiazepine treatment, particularly psychotherapy, is safer and as effective for most patients with anxiety disorders.” This Letter describes the utilization of benzodiazepines in BC from 1996 to 2002. Benzodiazepines may impair functional status by causing confusion, memory loss, dizziness, daytime sleepiness, falls/fractures and depression. Despite this potential for major harm and scant evidence

2004 Therapeutics Letter

7. Mild traumatic brain injury: review of the literature and a look at the WCB of BC data

Mild traumatic brain injury: review of the literature and a look at the WCB of BC data Mild traumatic brain injury: review of the literature and a look at the WCB of BC data Mild traumatic brain injury: review of the literature and a look at the WCB of BC data WCB Evidence Based Practice Group Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation WCB Evidence (...) Based Practice Group. Mild traumatic brain injury: review of the literature and a look at the WCB of BC data. Richmond, BC: WorkSafe BC 2003: 96 Authors' objectives The purpose of this paper is: to obtain published systematic reviews on mild traumatic brain injury (MTBI) (diagnostic criteria, assessment and treatment of MTBI) in the absence of any practical high quality systematic reviews, to obtain the highest quality or grades of evidence review of MTBI to form the medical portion of a more comprehensive MTBI

2003 Health Technology Assessment (HTA) Database.

8. The BC Community Pharmacy Asthma Study: a study of clinical, economic and holistic outcomes influenced by an asthma care protocol provided by specially trained community pharmacists in British Columbia

The BC Community Pharmacy Asthma Study: a study of clinical, economic and holistic outcomes influenced by an asthma care protocol provided by specially trained community pharmacists in British Columbia The BC Community Pharmacy Asthma Study: a study of clinical, economic and holistic outcomes influenced by an asthma care protocol provided by specially trained community pharmacists in British Columbia The BC Community Pharmacy Asthma Study: a study of clinical, economic and holistic outcomes (...) analysis. Study population The study population comprised asthma patients attending one of 27 HOP cooperatives. The pharmacies tried to recruit patients whose asthma was uncontrolled. Setting The setting was community pharmacies and secondary care. The economic study was carried out in British Columbia (BC), Canada. Dates to which data relate The effectiveness evidence related to 1999 to 2000. The dates to which the resource evidence related were unclear, but it is likely that evidence

2003 NHS Economic Evaluation Database.

9. Clinical and economic comparison of lenograstim-primed blood cells (BC) and bone marrow (BM) allogeneic transplantation

Clinical and economic comparison of lenograstim-primed blood cells (BC) and bone marrow (BM) allogeneic transplantation Clinical and economic comparison of lenograstim-primed blood cells (BC) and bone marrow (BM) allogeneic transplantation Clinical and economic comparison of lenograstim-primed blood cells (BC) and bone marrow (BM) allogeneic transplantation Faucher C, Fortanier C, Viens P, Le Corroller A G, Chabannon C, Camerlo J, Novakovitch G, Gastaut J A, Maraninchi D, Moatti J P, Blaise D (...) Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Using blood cells (BC) allogeneic transplantation in patients suffering from acute leukemia or chronic myeloid leukemia (CML) in CR1 or PR1. Type of intervention Treatment. Economic

1998 NHS Economic Evaluation Database.